Reversal SetupBuying here with a stop on any close below the 252 day moving average. I am looking for price to head back to the 195 area. SGEN has burned me recently but I am taking another shot at range lows. I like the rate of change divergence.
Biotech
CRSP short trade updated chartHere is the updated chart on CRSP short trade I posted on January 14th. It's been down 23% since the date it was posted. So far so good. First target was hit today and managed to keep above as I have expected. I expect more downside in days to come. XBI sector can break down anytime too now. Literally one red day will do. My next target is the bottom of the channel colored yellow. Once the selling gets momentum, it will be pretty swift downward move. Definitely can't fall a sleep behind the wheel right now in this market.
Have a good trades everyone,
T.
Vistagen (VTGN): My opinion NASDAQ:VTGN This isn't financial advice (hell no). I like this stock. The company has potential. This is a nice buying opportunity in non-expert opinion. So, I'm scooping up before their phase 3 trials.
Invest in the next scamThe chinese love powder made from endangered animals and trash plants , americans love their superfoods.
A plant called alfalfa (luzerne) that french farmers love to grow because it can get Nitrogen itself and it's cheap and packed with protein, they feed it to cattle, so to cows and also americans. Americans actually pay a high price to get supercheap leaves in powdered form.
Long gone are the days where scientists published a paper showing chicken like blondes more, to get average people interested in science, these days everyone is interested in science... And the result is quite amusing. Science has gotten politicised, the use of catchy words like "amazing" & "stunning" & "groundbreaking" in papers has grown 1000 fold (not even exagerating), there is a replication crisis, etc.
"Science" is the next big thing. I bet a study could show that when the average millenial sees the words "study shows" and "peer-reviewed" and "research suggests" he'll get a dopamine rush. Elon Musk sure cashed in on the "science & tech will save us all" large religious movement created by people abandonning the old religions.
Anything could happen, and nothing is too stupid. Dumb people think they are smart so it's a coinflip. For example we could go bet on homeopathy, try not to laugh while buying shares, but it can go either way. Lots of people are getting obsessed with health, this is a certainty. Several possibilities:
- "Conspiracy theorists", emboldened by sometimes being proven right when everyone calls them crazy and denies their claims, could believe in a conspiracy theory that expensive water is a valid medicament.
- "We're on the side of science" crowd, provided they hear some health authority or the media tell them so, will be 100% convinced homeopathy is a great super smart super science valid treatment.
- "We're on the side of science" crowd proudly claim homeopathy is pseudo-science and hurt the business, they could even ban it because it's "silly and no study shows and the WHO says"
If politicians decide the plebes take too much drugs (they do but the politicians take money from big pharma...) they could brainwash the "smart side of science non-conspiracy-theorists" clueless morons into buying water from scammy labs. It's just so hard not to laugh at the idea of people taking water medication.
You know, if they're going to be scared, and look for snakeoil superfoods and radioactive chemicals, might as well give them water, it won't hurt them.
It's actually a moral investment.
Other things could get big, how about "OMG study shows psilocybin cures depression let's all microdose mushrooms and also LSD because why not".
I heard "microdosing" was popular with tech executives as a magical boost to become smarter (AHEM!) and more productive.
Homeopathy... Mushrooms... Microdosing various lab-created drugs... Improvement microchips... Nanobots... We'll see what goes up. All of them?
The next bull cycle (50Y) is supposed to involve health. So this is important. Dumb irrealistic scams will, as always, go up way more (in %) than anything remotely legit.
People are unbelievably stupid, and it is getting worse, common sense is frowned upon, like literally, I can't believe this is real, you're a weirdo if you have common sense.
You cannot stop it. You can whine about it, or you can crack up and laugh hysterically while you take advantage of it for your own profit.
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases.
This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering from profound, medically refractory COVID-19 respiratory failure," Dr. Nijhawan said.
finance.yahoo.com
Significant and Rapid Reduction in Hepatitis B Surface AntigenInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.
Additional data will be submitted for presentation at an upcoming medical conference. A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year.
finance.yahoo.com
the world's first Phase 3 oral insulin studyOramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
Randomization of patients in the world's first Phase 3 oral insulin study conducted under FDA approved protocol
Announced today that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.
Efficacy data will become available after all patients have completed the first 6-month treatment period.
finance.yahoo.com
ARKG 1HROne of my favourite ETFs at the moment.
Cup and handle formed a while back. Still bullish imo.
I am long on this. Will add on dips.
Im Cathie Wood we trust.
ARKG 1HR One of my favourite ETFs at the moment.
Im in this long term.
I see big upside value in years to come. Will add on dips!
SYMJEPI Products Now Available in the WalgreensSYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the lowest price offered for epinephrine products through the Walgreens Prescriptions Savings Club, and the lowest price for epinephrine devices on the market1.
finance.yahoo.com
$NOVN - Long - Gapfill to 3 USD - 1/23/2021- Seems to be breaking out, watch for consolidation first at this support level
- It's a pennystock so manage risk
- Gap to fill, Cup & Handle, Bull flag
- fundamentals seem good
- Trigger is strong volume up on this bull flag
PT: 3.1
GL
AzurRx BioPharma Announces First Two Patients DosedAzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
Due to enrollment in the initial crossover trial being ahead of schedule, we are given an opportunity to thoroughly explore optimal doses and capsule types that will help guide our future development plans for MS1819 in a Phase 3 program. In the meantime, we will continue our preparation for a successful FDA meeting later this year.”
Topline data results for this study are anticipated in Q1 2021, as enrollment remains strong.
finance.yahoo.com
Understanding range highs and lows are all you need. #stocksBack on October 27th I made a post highlighting a potential reversal as we approached the range lows from back in June. Over the future months the stock tested the lows, found support, and is not heading toward highs. Range highs and lows and major support and resistance areas have value because they indicate where there is likely to be heavy order flow. In this case it AMGN reacted well and held the lows creating a great risk/reward opportunity.
AditxtScore™ Immune Monitoring Service Operational on February 1AditxtScore™ Immune Monitoring Service Will be Operational on February 1st
Company Plans to Offer Service through Channel Partners
The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus.
We’re currently in discussions with labs, hospitals and other channel partners around the world interested in incorporating AditxtScore™ into their offerings.
finance.yahoo.com
ArcticZymes $AZT beautifull breakout above key resistance 75NOKInteresting to see Q4 report for ArcticZymes to learn more about the use of their cod enzymes in Covid 19 vaccines
Obalon Therapeutics Surges On News Of Merger With ReShape LifeObalon Therapeutics Surges 75% On News Of Merger With ReShape Lifesciences
ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering
ReShape Lifesciences, a weight-loss solutions company, entered into a merger agreement with Obalon Therapeutics, under which ReShape and Obalon will combine in an all-stock transaction.
Under the agreement, which has been unanimously approved by the boards of both companies, existing ReShape stockholders will have majority ownership of the combined company.
Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol "RSLS."
The current directors and officers of ReShape will comprise the board of directors and executive management of the combined company.
www.nasdaq.com
finance.yahoo.com
BLA for Narsoplimab in HSCT-TMA Accepted for Priority Review Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
-- FDA sets PDUFA date of July 17, 2021 --
YTEN 10/10First pullback , second pullback and now we are on the third pullback .
That is the actual situation after getting a +93.10% performance over the course of the week.
Right now biotechnological and medical stocks are rising because of the news, but be careful on getting
into this stock, it might be too late. Usually stocks do not bounce a fourth time after three pullbacks.
Even though, if we analyze the situation using Elliot waves, we could see a new uprising wave, but it is possible because of the volume showing on the candles that are slowing down the downtrend.
And the last tool used to analyze this market was the Fibonacci retracement. If prices go below the 38.2 mark, it would be very unusual to see a new high.
Have a great day!
Sorrento could surge 275% in 2021, Here is why...H.C. Wainwright analyst Ram Selvaraju rates SRNE a Buy along with a $30 price target, which implies a 275% upside from current levels.
Factors behind the optimistic outlook:
1. Sorrento has a stake in two cell-based immunotherapy companies that could “drive value in Sorrento shares over the coming months.”
2. the analyst highlights Sorrento’s “burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology and COVID-19).”.
3. two rapid COVID 19 detection tests; COVI-STIX, for which the company filed for Emergency Use Authorization (EUA) in the U.S. in December, and COVI-TRACE, which Selvaraju claims could come in handy at any mass gathering event.
“We believe that the incentive to facilitate the large-scale and indeed ubiquitous deployment of the COVI-TRACE test is extremely high and governments worldwide may seek to implement this in their respective regions,” the 5-star analyst opined.
4. Other Covid-19 candidates include COVIGUARD - a SARS-CoV-2 neutralizing antibody, COVI-AMG - an affinity-matured version of the COVIGUARD neutralizing antibody, a neutralizing antibody cocktail named COVI-SHIELD and COVIDTRAP, an ACE2 receptor decoy, intended to imitate the mammalian ACE2 receptor that acts as the primary portal for the SARS-CoV-2 virus to penetrate human cells.
finance.yahoo.com
Oppenheimer Analyst Says buy, following of some positive dataOppenheimer 5-star Analyst Says BioNano Genomics is ready to Execute in 2021.
the latest move was decidedly upbeat. In Wednesday’s session, the stock took off to the tune of 40% following the publication of some positive data.
article which made side-by-side comparisons between Bionano’s optical genome mapping platform Saphyr and PacBio's HiFi chemistry revealed that Saphyr had the upper hand on several metrics.
Across 32 different human genomes, PacBio technologies found only 72% of the large SVs (structural variants) that Bionano’s optical genome mapping (OGM) detected.
Saphyr was also found to be better at locating indels in regions correlated to neurodevelopment.
Additionally, Saphyr appears to be more cost effective. The platform’s estimated cost of $500 per genome coming in far below the $10,000-20,000 per genome when HiFi and SMRT sequencing are put into action.
Oppenheimer’s Kevin DeGeeter believes the data should help Saphyr make further inroads in the “large SV research market.” The analyst views 2021 “largely as an execution year.”
We expect the data to support broader adoption of Saphyr for de novo sequencing and research applications. the 5-star analyst said.
“Furthermore, we expect 2021 to be an important year for adoption of Saphyr for clinical cytogenetics market based on a series of positive recent publications... Based on our current assessment of the competitive landscape, we do not believe long-read sequencing technologies can replicate Saphyr's performance and cost structure for digital cytogenetics testing.”
Accordingly, DeGeeter reiterated an Outperform (i.e. Buy) on BNGO shares, along with a $1.5 price target. The implication for investors? Strong upside of 113% .
Two other analysts have thrown the hat in with a BNGO review recently, one saying Buy and the other recommending a Hold -- all add up to a Moderate Buy consensus rating. Meanwhile, the average price target stands at $1.42, implying gains of 101% could be in the cards over the next 12 months.
finance.yahoo.com
FDA identifies "Assay Kit" able to detect SARS-CoV-2 mutationsU.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)
(FDA) published a safety communication (the "Communication") that identifies the Company’s Linea™ COVID-19 Assay Kit (the "Assay Kit") as one of only two tests marketed under the FDA’s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19.
Based on analysis conducted by the Company and FDA, one of the two S-gene targets (S1 and S2) of the Assay Kit has significantly reduced sensitivity in the presence of certain S-gene mutations, including a mutation found in the B.1.1.7 variant.
finance.yahoo.com
